



## MEDIA CONTACTS

Liz Larkin  
Ikaria  
908-238-6645  
[Liz.Larkin@ikaria.com](mailto:Liz.Larkin@ikaria.com)

Jason Rando/Catherine Bright  
The Ruth Group  
646-536-7025/7013  
[jrando@theruthgroup.com](mailto:jrando@theruthgroup.com)  
[cbright@theruthgroup.com](mailto:cbright@theruthgroup.com)

**Ikaria Wins Second Consecutive AARC Zenith Award**  
*- Award Presented at 53rd International Respiratory Congress -*

**Clinton, NJ, January 17, 2008** – Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that it has been awarded the American Association for Respiratory Care (AARC) Zenith Award for the second consecutive year. The 2007 Zenith Award was presented to Ikaria at the AARC's 53rd Annual International Respiratory Congress in Orlando, Florida on December 3, 2007. Ikaria was one of five companies to win the award in a field of more than 400 eligible organizations.

The Zenith Award, AARC's top industry recognition award, is presented to companies selected by the 44,000 members of AARC based upon the quality of equipment and/or supplies, accessibility and helpfulness of sales personnel, responsiveness, service record, truth in advertising and support of the respiratory care profession.

"We are honored that the AARC membership has chosen to recognize us for the second year in a row with this prestigious award," said Ikaria's Executive Chairman David Shaw. "The Zenith Award reflects Ikaria's continued leadership in the respiratory care market, and its commitment to providing respiratory therapists with the highest quality service, continuing education programs and critical care technology. It is a source of great satisfaction for everyone at Ikaria to be in a position to serve the needs of the critically ill."

### **About INOmax**

INOmax, in conjunction with ventilatory support and other appropriate agents, is used for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension.

INOMax is designed to help critically ill newborns breathe more effectively by dilating the blood vessels of the lungs, which improves oxygen uptake and oxygen supply to the tissues of the body. INOMax therapy has been shown to reduce the need for a highly invasive surgical procedure known as extracorporeal membrane oxygenation, or ECMO. During ECMO, an infant's blood is mechanically oxygenated by connecting the baby to a heart-lung machine.

INOMax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO<sub>2</sub>) forms rapidly in gas mixtures containing nitric oxide and oxygen and thus may cause airway inflammation and damage. Methemoglobin, NO<sub>2</sub>, and the fraction of inspired oxygen (FiO<sub>2</sub>) should be monitored during nitric oxide administration.

For more information on INOMax, including important safety and complete prescribing information, please visit [INOMax.com](http://INOMax.com).

**About Icaria Holdings, Inc.**

Icaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOMax<sup>®</sup> (nitric oxide) for inhalation, is an FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to marketing and selling its INOMax product, Icaria is engaged in both Phase II trials with Covox<sup>®</sup> (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H<sub>2</sub>S) for various indications. Icaria has a staff of over 300 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Icaria, please visit [www.ikaria.com](http://www.ikaria.com).

###